Key result
Yangxinshi proves non-inferior to trimetazidine for improving exercise tolerance in CHD patients after PCI.
Why the study?
Optimizing medication to improve exercise tolerance in patients with CHD after PCI is limited.
Does Yangxinshi improve exercise tolerance compared to trimetazidine in patients with coronary heart disease after percutaneous coronary intervention?
RCT (n=681)
double-blind, double-dummy
randomized
Yes
Does Yangxinshi improve exercise tolerance compared to trimetazidine in patients with coronary heart disease after percutaneous coronary intervention?
In patients with CHD after PCI, Yangxinshi was non-inferior to trimetazidine in improving exercise tolerance over 24 weeks, and was associated with better patient-reported mental health outcomes.
Answers are grounded in this paper and cite their sources.
Yangxinshi matches trimetazidine for exercise capacity gains; confirms equivalence in this RCT and supports expanded TCM outcome trials.
BACKGROUND: Optimizing medication to improve exercise tolerance in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI) is limited. Yangxinshi tablets, an herbal-based oral medicine, relieve symptoms of angina might be that they can improve energy metabolism of the ischemic myocardium. We conducted a randomized trial to assess the efficacy and safety of Yangxinshi vs. trimetazidine in improving exercise tolerance in patients with CHD after PCI. METHODS: This prospective, randomized, double-blind, double-dummy, multicenter, non-inferiority study enrolled patients aged 18-75 years with CHD who underwent their first PCI within 2 months of diagnosis. Patients were randomized to Yangxinshi plus trimetazidine-placebo or trimetazidine plus Yangxinshi-placebo for 24 weeks. The primary endpoint was the change in metabolic equivalents (METs) assessed by cardiopulmonary exercise test (CPET) between 0 and 24 weeks. Secondary endpoints were comprehensive variables of the CPET, health status and adverse events. This study has been registered at ClinicalTrials. gov (NCT03809273). RESULTS: Between August 1, 2019, and March 31, 2022, a total of 681 patients were randomized to Yangxinshi (n = 341) or trimetazidine (n = 340). After 24 weeks, the exercise tolerance of patients increased by 0.77±1.25 METs in the Yangxinshi group and 0.76±1.00 METs in the trimetazidine group (difference, 0.01; 95 % confidence interval [CI], -0.17 to 0.19), meeting the predefined non-inferiority threshold. Better outcomes were observed in the Yangxinshi group compared with the trimetazidine group for patient-reported depression (PHQ-9; -1.88±3.32 vs. -0.93±3.68; p < 0.001) and anxiety (GAD-7; -1.70±3.26 vs. -0.39±3.29; p < 0.001). Adverse events were similar in both groups. CONCLUSIONS: In patients with CHD after PCI, Yangxinshi was non-inferior to trimetazidine in improving exercise tolerance during the 24-week treatment period. Notably, patients in the Yangxinshi group showed a better mental health profile compared with trimetazidine recipients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted an RCT in coronary heart disease after percutaneous coronary intervention (n=681). Yangxinshi vs. trimetazidine was evaluated on change in metabolic equivalents (METs) assessed by cardiopulmonary exercise test (CPET) between 0 and 24 weeks (MD 0.01, 95% CI -0.17 to 0.19). Yangxinshi was non-inferior to trimetazidine in improving exercise tolerance in patients with CHD after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: